Academisch Ziekenhuis Leiden
Leiden, The Netherlands
Recruiting
Study on Ureter Imaging with Nizaracianine Triflutate for Patients 18+ Undergoing Abdominopelvic Surgery
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
What is this trial about?
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on improving the visualization of the ureters, which are tubes that carry urine from the kidneys to the bladder, during certain types of surgeries in the abdomen and pelvis. The study involves the use of a special medication called nizaracianine triflutate, which is given through an injection into a vein. This medication is designed to help surgeons see the ureters more clearly by using a special type of light called near-infrared fluorescent light. The trial aims to determine how safe and effective this medication is in helping surgeons identify the ureters during surgery.
Participants in the study will receive the medication in up to three doses while they are undergoing surgery. The study will compare the results with those of a placebo group to assess the benefits of using nizaracianine triflutate. The goal is to find the best dose that provides a clear view of the ureters without causing any harm to the patients. This could potentially make surgeries safer by reducing the risk of accidental damage to the ureters.
In addition to nizaracianine triflutate, the study also uses a solution called Glucose 5%, which is a common sterile fluid used in medical settings. The trial will monitor how well the medication works in helping surgeons see the ureters and whether it can reduce the need for more invasive procedures during surgery. The study is open to adults aged 18 and older who are scheduled for certain types of abdominal or pelvic surgeries.
The research process
The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.
Who can join the trial?
9 criteria
- Must be 18 years old or older.
- Scheduled to have a necessary abdominopelvic surgical procedure. This is a surgery in the area of the abdomen and pelvis.
- For Phase 2, the surgery should last at least 2 hours and involve working on one or both ureters. Ureters are tubes that carry urine from the kidneys to the bladder.
- For Phase 3, the surgery can be of any length, but one or more ureters should be seen during the procedure.
- The surgery can be open (traditional) or MIS (minimally invasive surgery), which includes robotic surgery.
- Both ureters should be present and working properly.
- Must be able and willing to give informed consent before any study-specific procedures. This means understanding and agreeing to participate in the study.
- Results from initial laboratory tests should be normal, or if not, they should be considered not important for health by the study doctors.
- Women who can have children must have a negative pregnancy test.
Who cannot join the trial?
5 criteria
- Patients who are not within the specified age range for the study.
- Patients who are part of a vulnerable population, which means groups that might need special protection or care.
- Patients who have any medical conditions that could interfere with the study, such as issues with urinary tract imaging.
- Patients who are not able to follow the study procedures or instructions.
- Patients who have any other health conditions that the study doctors think might make it unsafe for them to participate.
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
Verified sites
All sites with verified contact details – recruitment status may not be available; ask directly
Responsive Responsive Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Rotterdam, The NetherlandsVerified Isala Klinieken Stichting
Zwolle, The Netherlands
Trial locations
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
RecruitingNot finding your country?
Not sure what to do next?
Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
Investigated drugs
Nizaracianine is a medication being tested in this clinical trial. It is given through an intravenous injection and is used to help doctors see the ureters more clearly during certain types of surgeries in the abdomen and pelvis. The medication works by using a special type of light called near-infrared (NIR) fluorescent light, which makes the ureters glow and easier to identify. This can help surgeons avoid damaging the ureters during surgery. The trial is focused on checking how safe and effective this medication is and finding the best dose to use for this purpose.
What is already known about the treatment
Nizaracianine Triflutate – This medication is administered intravenously in up to three divided doses. It is currently being studied in a Phase 2/3 clinical trial to evaluate its safety and effectiveness in visualizing the ureters during abdominopelvic surgical procedures. The main therapeutic indication is to enhance the visualization of ureter anatomy and function using near-infrared (NIR) fluorescent light. At the molecular level, nizaracianine works by emitting fluorescence when exposed to NIR light, which helps in clearly delineating the ureters during surgery. It is classified pharmacologically as a fluorescent imaging agent.
Investigated diseases
Urinary Tract Imaging – This is not a disease but a diagnostic procedure used to visualize the urinary tract, including the kidneys, ureters, bladder, and urethra. It helps in identifying abnormalities such as blockages, stones, or structural issues. The imaging can be done using various techniques like X-rays, CT scans, or MRIs. During the procedure, a contrast dye may be used to enhance the visibility of the urinary tract structures. This process is crucial for planning surgeries or other medical interventions. It provides detailed images that assist healthcare providers in diagnosing and managing urinary tract conditions.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IVTrial ID2023-503241-63-00Protocol codeZW800-001Estimated enrolment336 patientsSponsorCuradel Surgical Innovations B.V.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?